Drug Rescue
Innovation Worth Watching: How Ignota Labs Leverages AI to Rescue Promising but Failing Drugs
David Alvaro, Ph.D.
Pharma's Almanac
PAO-08-25-NI-06Aug 06, 2025
Exosomes
Exosomes: A Promising Natural Nanoparticle Delivery System
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-07-25-NI-04Jul 14, 2025
IBD
Glycocaging: A Smart Chemistry Platform for Safer, Smarter IBD Treatments
David Alvaro, Ph.D.
Pharma's Almanac
PAO-07-25-NI-03Jul 14, 2025
Biologics LAIs
Extending the Reach: The Next Generation of Long-Acting Injectable Depots for Biologics
David Alvaro, Ph.D.
Pharma's Almanac
PAO-07-25-NI-02Jul 02, 2025
Exosomes
Nature’s Nanocarriers: The Evolving Role of Exosomes in Targeted Drug Delivery
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-25-NI-04May 13, 2025
Partnership
Recipharm and PLG Announce Strategic Partnership to Accelerate Development Projects
Recipharm AB
PR-05-25-NI-01May 13, 2025
Analytical
Leveraging Advanced GMP Release and Stability Testing Methods to Accelerate New Drug Development
Carsten Kroeger, Dr. rer. nat.; Gerhard Sax, Dr. rer. nat.
Coriolis Pharma
PAO-04-25-CL-03Apr 15, 2025
Maternal Health
Maternal Mandate: Elevating Innovation, Equity, and Investment in Women’s Health
David Alvaro, Ph.D.
Pharma's Almanac
PAO-04-25-NI-04Apr 08, 2025
Particle Analysis
Advancing Subvisible Particle Characterization with Artificial Intelligence
Daniel Weinbuch, Ph.D.
Coriolis Pharma
PAO-03-25-CL-02Mar 11, 2025
Oncology
From Coley’s Toxins to mRNA: Reflecting on the History of Cancer Vaccines
David Alvaro, Ph.D.
Pharma's Almanac
PAO-25-30-03Mar 02, 2025
Personalized
Personalized Medicine and the CDMO: Adapting to a New Era of Healthcare
Ola Tuvesson; Isa Lindgren, Ph.D.
NorthX Biologics
PAO-01-25-CL-09Feb 14, 2025
Drug Development
Nektar Therapeutics Receives Fast Track Designation for the Treatment of Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics
PR-02-25-NI-07Feb 10, 2025
Drug Development
FDA Accepts Integral Molecular's Membrane Proteome Array™ Qualification Plan, Advancing Approval Platform of Drug Development Tool
Integral Molecular
PR-02-25-NI-04Feb 08, 2025
Developability
Streamlining Drug Development with Integrated In Silico and Laboratory Developability Assessments
Andrea Arsiccio, Ph.D.,; Eva Keilhauer, Ph.D.; Kristian Le Vay, Ph.D.
Coriolis Pharma
PAO-01-25-CL-12Jan 27, 2025
Drug Development
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
REGENXBIO
PR-01-25-NI-12Jan 14, 2025
Clinical Trials
New SELECT trial analysis with semaglutide 2.4 mg showed a reduction in hospital admissions with heart disease and overweight
Novo Nordisk
PR-10-24-NI-74Nov 05, 2024
Clinical Trials
TREMFYA is the first and only IL-23 inhibitor to demonstrate robust results with regimen in both induction and maintenance
Johnson & Johnson
PR-10-24-NI-64Oct 28, 2024
FDA
U.S. Food and Drug Administration
U.S. Food & Drug Administration
PR-10-24-NI-44Oct 14, 2024
FDA
SystImmune, Inc. Announces FDA Clearance of IND Application for BL-M11D1 in Relapsed/Refractory Acute Myeloid Leukemia
Systimmune, Inc.
PR-10-24-NI-42Oct 14, 2024
Financing
AMD Drugs Market to Hit USD 17.37 Billion by 2029 with 10.7% CAGR | MarketsandMarkets™
MarketsandMarkets™
PR-09-24-NI-22Sep 27, 2024